Welcome!

News Feed Item

Neptune Announces Second Quarter Results

Cannabis Business Moves Forward with the Approval of $5M Investment

LAVAL, QUEBEC -- (Marketwired) -- 11/14/17 --

Q2 Financial and Operational Highlights for the 3-month period ended September 30, 2017 compared to the 3-month period ended August 31, 2016(1)

--  Sale of bulk krill oil manufacturing and distribution activities
    completed. Sherbrooke site retained for new business focus. 
--  As a result of the sale, Nutraceutical Segment debt reduced to $7.0
    million from $21.7 million, and cash boosted to $34.3 million from $4.5
    million as of Sept. 30, 2017. 
--  Revenues of $6.8 million, down from $11.6 million last year due to the
    krill oil sale; revenues up 4.0% sequentially versus 1Q18. 
--  Gain of $23.9 million realized from the sale of the krill oil business. 
--  Net income of $20.0 million versus net loss of $0.7 million in the prior
    year. 
--  Non-IFRS operating loss(2) was $0.2 million compared to an Adjusted
    EBITDA(2) of $0.8 million in the prior year. 
--  Cannabis business team appointed: Michel Timperio as President, Melody
    Harwood as Head of Scientific & Regulatory Affairs and Eric Krudener as
    Director of Product and Brand Development. 

Post Quarter End Highlights:

--  Board of Directors approves $5 million investment for plant conversion
    to cannabis-derived oil production. 
--  Company schedules business review day titled "The Cannabis Roadmap" in
    New York City on November 28, 2017. 

(1) Neptune Nutraceutical Segment.                                          
(2) See "Caution Regarding Non-IFRS Financial Measures" and "Reconciliation 
    of net income (loss) to Adjusted EBITDA or non-IFRS operating loss"     
    which follow.                                                           

Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (NASDAQ:NEPT)(TSX:NEPT), today announced its financial and operating results for the 3-month and 6-month periods ended September 30, 2017. All amounts are in Canadian dollars.

Nutraceutical Segment

"Our second quarter of fiscal 2018 and the weeks that followed saw us complete a number of significant transformational actions. We successfully exited the krill oil manufacturing business, we meaningfully strengthened our balance sheet, and we moved full steam ahead with our work to enter the highly profitable legal cannabis space, a segment characterized by its already established size and excellent growth potential," said Mr. Hamilton, President and Chief Executive Officer of Neptune. "This work has included management staffing, potential supply partnerships and customer engagement, engineering and design. Regarding a critical kickoff step in this process forward, our board recently authorized $5 million of capital investment to adapt our Sherbrooke facility from krill oil to cannabis oil extraction. We will share further details of these plans, and more at our upcoming business review day to be held in New York City later this month."

At the same time, our Solutions Business and Ingredients products such as MaxSimil continue to perform well. Adjusted for the sale of the krill oil manufacturing business, our Nutraceutical revenue in the second quarter rose 10% versus the first quarter. Our objective for our Solutions Business remains to grow revenue at a double-digit rate for the full year. Overall, we remain excited about the road before us and are confident that our technological, regulatory, and extraction expertise will serve to differentiate Neptune as a premium competitor in both our existing nutraceutical businesses and the cannabis oil opportunity we are targeting," concluded Mr. Hamilton.

"The proceeds received for the divestiture of our krill business have significantly solidified and de-leveraged our balance sheet. Considering announced capital expenditures for the cannabis business as well investment to support its ramp-up, some debt repayment and other business assumptions, we anticipate that the cash position for our Nutraceutical segment will be between $23 and $24 million at year-end on March 31, 2018, which provides ample financial flexibility to execute our business plan," indicated Mario Paradis, Vice President and Chief Financial Officer.

Nutraceutical Business Results

As previously announced, Neptune transitioned to a new fiscal year-end as at March 31, 2017. Financial information for the three-month and six-month periods ended September 30, 2016 has not been included in these financial statements for the following reasons: (i) the three-month and six-month periods ended August 31, 2016 provides a meaningful comparison for the three-month and six-month periods ended September 30, 2017; (ii) there are no significant factors, seasonal or otherwise, that would impact the comparability of information if the results for the three-month and six-month periods ended September 30, 2016 were presented in lieu of results for the three-month and six-month periods ended August 31, 2016; and (iii) it was not practicable or cost justified to prepare this information.

Second Quarter Financial Results

--  Nutraceutical revenues were $6.8 million for the three-month period
    ended September 30, 2017, versus $11.6 million for the three-month
    period ended August 31, 2016. 
--  Net income was $20.0 million for the current quarter, versus a net loss
    of $0.7 million in the prior year. 
--  Non-IFRS operating loss(1) was $0.2 million for the current quarter,
    compared to an Adjusted EBITDA(1) of $0.8 million in the prior year. 

The nutraceutical segment second quarter Adjusted EBITDA(1) decrease was mainly attributable to the sales and gross margin decrease after the transaction concluded with Aker BioMarine. The nutraceutical segment second quarter net income includes a gain on sale of assets of $23.9 million and impairment loss on inventories of $1.7 million.

Year-to-Date Financial Results

--  Nutraceutical revenues were $13.3 million for the six-month period ended
    September 30, 2017, versus $22.8 million for the six-month period ended
    August 31, 2016. 
--  Net income was $18.9 million for the six-month period ended September
    30, 2017, versus a net loss of $1.9 million in the prior year. 
--  Adjusted EBITDA(1) was $0.5 million for the six-month period ended
    September 30, 2017, compared to $1.9 million in the prior year. 

The nutraceutical segment Year-to-Date Adjusted EBITDA(1) decrease was mainly attributable to the sales and gross margin decrease after the transaction concluded with Aker BioMarine. The nutraceutical segment Year-to-Date net income includes a gain on sale of assets of $23.9 million and impairment loss on inventories of $1.7 million.

Consolidated Results (including Acasti Pharma)

Second Quarter Financial Results

--  Consolidated revenues totalled $6.8 million for the three-month period
    ended September 30, 2017, versus $11.6 million for the three-month
    period ended August 31, 2016. 
--  Net income was $16.1 million for the current quarter, versus a net loss
    of $2.4 million in the prior year. 
--  Non-IFRS operating loss(1) was $3.6 million for the current quarter,
    versus $0.9 million in the prior year. 

On a consolidated basis, the current quarter includes a Non-IFRS operating loss(1) of $3.4 million and a net loss of $4.5 million for Neptune's subsidiary, Acasti, which is actively engaged in clinical studies and research and development. For the three-month period ended August 31, 2016, Acasti recorded a Non-IFRS operating loss(1) of $1.6 million and a net loss of $2.3 million.

Year-to-Date Financial Results

--  Consolidated revenues were $13.3 million for the six-month period ended
    September 30, 2017, versus $22.8 million for the six-month period ended
    August 31, 2016. 
--  Net income was $12.8 million for the six-month period ended September
    30, 2017, versus a net loss of $6.2 million in the prior year. 
--  Non-IFRS operating loss(1) was $5.1 million for the six-month period
    ended September 30, 2017, compared to $2.0 million in the prior year. 

On a consolidated basis, the six-month period ended September 30, 2017 includes a Non-IFRS operating loss(1) of $5.5 million and a net loss of $7.3 million for Neptune's subsidiary, Acasti, which is actively engaged in clinical studies and research and development. For the six-month period ended August 31, 2016, Acasti recorded a Non-IFRS operating loss(1) of $3.9 million and a net loss of $5.5 million.

Consolidated cash and cash equivalents, including $2.4 million of restricted short-term investments, were $39.6 million as at September 30, 2017, with $34.3 million for the nutraceutical segment and $5.3 million for Acasti. Acasti raised additional funds during the thirteen-month period ended March 31, 2017 and is working towards development of strategic partner relationships and plans to raise additional funds in the future, but there can be no assurance as to when or whether Acasti will complete any financing or strategic collaborations. As a result, there exists a material uncertainty that casts substantial doubt about Acasti's ability to continue as a going concern and, therefore, realize its assets and discharge its liabilities in the normal course of business.

(1) See "Caution Regarding Non-IFRS Financial Measures" and "Reconciliation 
    of net income (loss) to Adjusted EBITDA or non-IFRS operating loss"     
    which follow.                                                           

Caution Regarding Non-IFRS Financial Measures

The Corporation uses an adjusted financial measure, Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) called non-IFRS operating loss when the Corporation or segment is in a loss position, to assess its operating performance. This non-IFRS financial measure is directly derived from the Corporation's financial statements and is presented in a consistent manner. The Corporation uses this measure for the purposes of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. This measure also helps the Corporation to plan and forecast for future periods as well as to make operational and strategic decisions. The Corporation believes that providing this information to investors, in addition to IFRS measures, allows them to see the Corporation's results through the eyes of management, and to better understand its historical and future financial performance.

Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than IFRS do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation. The Corporation uses Adjusted EBITDA (or non-IFRS operating loss when in a loss position) to measure its performance from one period to the next without the variation caused by certain adjustments that could potentially distort the analysis of trends in our operating performance, and because the Corporation believes it provides meaningful information on the Corporation financial condition and operating results. Neptune's method for calculating Adjusted EBITDA (or non-IFRS operating loss) may differ from that used by other corporations.

Neptune obtains its Consolidated Adjusted EBITDA (or non-IFRS operating loss) measurement by adding to net income (loss), finance costs, depreciation, amortization and impairment loss and income taxes and by subtracting finance income. Other items such as insurance recoveries from plant explosion, royalty settlements, net gain on sale of assets, legal fees related to royalty settlements, tax credits recoverable from prior years and acquisition costs that do not impact core operating performance of the Corporation are excluded from the calculation as they may vary significantly from one period to another. Finance income/costs include foreign exchange gain (loss) and change in fair value of derivatives. Neptune also excludes the effects of certain non-monetary transactions recorded, such as stock-based compensation, from its Adjusted EBITDA (or non-IFRS operating loss) calculation. The Corporation believes it is useful to exclude this item as it is a non-cash expense. Excluding this item does not imply it is non-recurring.

Conference Call Details

Neptune will be holding a conference call on November 14, 2017, at 5:00 PM (EST) to discuss its second quarter results for the three-month and six-month periods ended September 30, 2017.

Date:     Tuesday, November 14, 2017                                        
                                                                            
Time:     5:00 PM Eastern Standard Time                                     
                                                                            
Call:     1 (877) 223-4471 (within Canada & the U.S.)                       
          1 (647) 788-4922 (Outside Canada and the U.S.)                    
                                                                            
Webcast:  A live audio webcast and presentation of the results can be       
          accessed at:                                                      
          http://neptunecorp.com/en/investors/events-and-presentations/

A replay of the call will be available for replay two hours after the call's completion, until December 14, 2017. The telephone numbers to access the replay of the call are 1 (416) 621-4642 or 1 (800) 585-8367 (toll-free), Conference ID 90228278. The archive of the webcast, along with its accompanying presentation, will also be made available immediately in the Investors section of Neptune's website under Investor Events and Presentations.

About Neptune Technologies & Bioressources Inc.

Neptune is a wellness products company, with more than 50 years of combined experience in the industry. The Company develops turnkey solutions available in various unique delivery forms, offers specialty ingredients such as MaxSimil®, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and a variety of other marine and seed oils. Neptune also sells premium krill oil directly to consumers through web sales at www.oceano3.com. Leveraging our scientific, technological and innovative expertise Neptune is working to develop unique extractions in high potential growth segments such as in the medical cannabis field.

Neptune is also pursuing opportunities in the prescription drug markets, through its 34% owned subsidiary Acasti Pharma Inc. ("Acasti"). Acasti focuses on the research, development and commercialization of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia.

The Company's head office is located in Laval, Quebec.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Neptune's latest Annual Information Form (the "AIF"), which also forms part of Neptune's latest annual report on Form 40-F, and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Neptune's website at www.neptunecorp.com. All forward-looking statements in this press release are made as of the date of this press release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors" and in our MD&A for the interim period ended September 30, 2017 under "Risks and uncertainties".

Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.

Reconciliation of net income (loss) to non-IFRS operating loss(1)           
(Expressed in thousands of dollars)                                         
                                                                            
Three-month period ended September 30, 2017                                 
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                                  Inter-segment             
                    Nutraceutical Cardiovascular   eliminations       Total 
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                $              $              $           $ 
----------------------------------------------------------------------------
Total revenues              6,795              -              -       6,795 
Gross margin                  408              -              -         408 
R&D expenses                 (375)        (3,385)           581      (3,179)
R&D tax credits and                                                         
 grants                        30             36              -          66 
SG&A                       (2,976)        (1,037)             -      (4,013)
Other income - net                                                          
 gain on sale of                                                            
 assets                    23,871              -              -      23,871 
Income (loss) from                                                          
 operating                                                                  
 activities                20,958         (4,386)           581      17,153 
Net finance cost             (908)          (120)            (1)     (1,029)
Income taxes                   (7)             -              -          (7)
Net income (loss)          20,043         (4,506)           580      16,117 
                                                                            
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Adjusted EBITDA(1)                                                          
 (non-IFRS                                                                  
 operating loss)(1)                                                         
 calculation                                                                
Net income (loss)          20,043         (4,506)           580      16,117 
Add (deduct):                                                               
  Depreciation and                                                          
   amortization               809            667           (581)        895 
  Finance costs               915            159              -       1,074 
  Finance income               (9)           (14)             -         (23)
  Change in fair                                                            
   value of                                                                 
   derivative                                                               
   assets and                                                               
   liabilities                  2            (25)             1         (22)
  Stock-based                                                               
   compensation               221            295              -         516 
  Income taxes                  7              -              -           7 
  Impairment loss                                                           
   on inventories           1,719              -              -       1,719 
  Other income -                                                            
   net gain on sale                                                         
   of assets              (23,871)             -              -     (23,871)
----------------------------------------------------------------------------
Non-IFRS operating                                                          
 loss(1)                     (164)        (3,424)             -      (3,588)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
(1) See "Caution Regarding Non-IFRS Financial Measures".                    
                                                                            
                                                                            
Reconciliation of net loss to Adjusted EBITDA(1)or non-IFRS operating       
loss(1)                                                                     
(Expressed in thousands of dollars)                                         
                                                                            
Three-month period ended August 31, 2016                                    
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                                  Inter-segment             
                    Nutraceutical Cardiovascular   eliminations       Total 
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                $              $              $           $ 
----------------------------------------------------------------------------
Total revenues             11,587              4              -      11,591 
Gross margin                2,587              4              -       2,591 
R&D expenses                 (366)        (1,621)           581      (1,406)
R&D tax credits and                                                         
 grants                        10             23              -          33 
SG&A                       (2,496)          (856)             -      (3,352)
Loss from operating                                                         
 activities                  (265)        (2,450)           581      (2,134)
Net finance income                                                          
 (cost)                      (395)           120             (2)       (277)
Income taxes                   (8)             -              -          (8)
Net loss                     (668)        (2,330)           579      (2,419)
                                                                            
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Adjusted EBITDA(1)                                                          
 (non-IFRS                                                                  
 operating loss)(1)                                                         
 calculation                                                                
Net loss                     (668)        (2,330)           579      (2,419)
Add (deduct):                                                               
  Depreciation and                                                          
   amortization               767            614           (581)        800 
  Finance costs               683              2            (38)        647 
  Finance income             (320)           (57)            38        (339)
  Change in fair                                                            
   value of                                                                 
   derivative                                                               
   assets and                                                               
   liabilities                 32            (65)             2         (31)
  Stock-based                                                               
   compensation               253            210              -         463 
  Income taxes                  8              -              -           8 
  Acquisition costs            14              -              -          14 
----------------------------------------------------------------------------
Adjusted EBITDA(1)                                                          
 (non-IFRS                                                                  
 operating loss)(1)           769         (1,626)             -        (857)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
(1) See "Caution Regarding Non-IFRS Financial Measures".                    

                                                                            
                                                                            
Reconciliation of net income (loss) to Adjusted EBITDA(1)or non-IFRS        
operating loss(1)                                                           
(Expressed in thousands of dollars)                                         
                                                                            
Six-month period ended September 30, 2017                                   
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                                  Inter-segment             
                    Nutraceutical Cardiovascular   eliminations       Total 
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                $              $              $           $ 
----------------------------------------------------------------------------
Total revenues             13,326              -              -      13,326 
Gross margin                2,851              -              -       2,851 
R&D expenses                 (787)        (5,391)         1,161      (5,017)
R&D tax credits and                                                         
 grants                        50             60              -         110 
SG&A                       (5,797)        (1,853)             -      (7,650)
Other income - net                                                          
 gain on sale of                                                            
 assets                    23,871              -              -      23,871 
Income (loss) from                                                          
 operating                                                                  
 activities                20,188         (7,184)         1,161      14,165 
Net finance cost           (1,323)          (100)            (5)     (1,428)
Income taxes                   13              -              -          13 
Net income (loss)          18,878         (7,284)         1,156      12,750 
Total assets               99,408         19,758        (11,294)    107,872 
Cash, cash                                                                  
 equivalents and                                                            
 restricted short-                                                          
 term investments          34,271          5,329              -      39,600 
Working capital(2)         32,885          2,461              1      35,347 
                                                                            
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Adjusted EBITDA(1)                                                          
 (non-IFRS                                                                  
 operating loss)(1)                                                         
 calculation                                                                
Net income (loss)          18,878         (7,284)         1,156      12,750 
Add (deduct):                                                               
  Depreciation and                                                          
   amortization             1,748          1,335         (1,161)      1,922 
  Finance costs             1,496            289              -       1,785 
  Finance income              (17)           (30)             -         (47)
  Change in fair                                                            
   value of                                                                 
   derivative                                                               
   assets and                                                               
   liabilities               (156)          (159)             5        (310)
  Stock-based                                                               
   compensation               582            331              -         913 
  Income taxes                (13)             -              -         (13)
  Impairment loss                                                           
   on inventories           1,719              -              -       1,719 
  Other income -                                                            
   net gain on sale                                                         
   of assets              (23,871)             -              -     (23,871)
  Legal fees                                                                
   related to                                                               
   royalty                                                                  
   settlements                 91              -              -          91 
----------------------------------------------------------------------------
Adjusted EBITDA(1)                                                          
 (non-IFRS                                                                  
 operating loss)(1)           457         (5,518)             -      (5,061)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
(1) See "Caution Regarding Non-IFRS Financial Measures".                    
(2) The working capital is presented for information purposes only and      
    represents a measurement of the Corporation's short-term financial      
    health mostly used in financial circles. The working capital is         
    calculated by subtracting current liabilities from current assets.      
    Because there is no standard method endorsed by IFRS, the results may   
    not be comparable to similar measurements presented by other public     
    companies.                                                              
                                                                            
                                                                            
                                                                            
Reconciliation of net loss to Adjusted EBITDA(1)or non-IFRS operating       
loss(1)                                                                     
(Expressed in thousands of dollars)                                         
                                                                            
Six-month period ended August 31, 2016                                      
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                                  Inter-segment             
                    Nutraceutical Cardiovascular   eliminations       Total 
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                $              $              $           $ 
----------------------------------------------------------------------------
Total revenues             22,841              7              -      22,848 
Gross margin                6,104              7              -       6,111 
R&D expenses                 (770)        (4,040)         1,161      (3,649)
R&D tax credits and                                                         
 grants                        19             47              -          66 
SG&A                       (5,686)        (1,423)             -      (7,109)
Loss from operating                                                         
 activities                  (333)        (5,409)         1,161      (4,581)
Net finance cost           (1,285)           (75)            (3)     (1,363)
Income taxes                 (300)             -              -        (300)
Net loss                   (1,918)        (5,484)         1,158      (6,244)
Total assets               87,681         23,552        (13,865)     97,368 
Cash, cash                                                                  
 equivalents and                                                            
 restricted short-                                                          
 term investments           7,125          8,124              -      15,249 
Working capital(2)         14,074          6,047              -      20,121 
                                                                            
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Adjusted EBITDA(1)                                                          
 (non-IFRS                                                                  
 operating loss)(1)                                                         
 calculation                                                                
Net loss                   (1,918)        (5,484)         1,158      (6,244)
Add (deduct):                                                               
  Depreciation and                                                          
   amortization             1,532          1,223         (1,161)      1,594 
  Finance costs             1,251            279            (83)      1,447 
  Finance income               (1)          (106)            83         (24)
  Change in fair                                                            
   value of                                                                 
   derivative                                                               
   assets and                                                               
   liabilities                 35            (98)             3         (60)
  Stock-based                                                               
   compensation               670            275              -         945 
  Income taxes                300              -              -         300 
  Acquisition costs            38              -              -          38 
----------------------------------------------------------------------------
Adjusted EBITDA(1)                                                         
(non-IFRS operating                                                         
 loss)(1)                   1,907         (3,911)             -      (2,004)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
(1) See "Caution Regarding Non-IFRS Financial Measures".                    
(2) The working capital is presented for information purposes only and      
    represents a measurement of the Corporation's short-term financial      
    health mostly used in financial circles. The working capital is         
    calculated by subtracting current liabilities from current assets.      
    Because there is no standard method endorsed by IFRS, the results may   
    not be comparable to similar measurements presented by other public     
    companies.                                                              

Contacts:
Neptune Wellness Solutions
Mario Paradis
VP & CFO, Neptune
1.450.687.2262 x236
[email protected]

Investor Relations Contact (Canada)
Pierre Boucher
MaisonBrison
1.514.731.0000
[email protected]

Investor Relations Contact (U.S.)
Ed McGregor/Jody Burfening
LHA
1.212.838.3777
[email protected]

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
SYS-CON Events announced today that Evatronix will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Evatronix SA offers comprehensive solutions in the design and implementation of electronic systems, in CAD / CAM deployment, and also is a designer and manufacturer of advanced 3D scanners for professional applications.
"I focus on what we are calling CAST Highlight, which is our SaaS application portfolio analysis tool. It is an extremely lightweight tool that can integrate with pretty much any build process right now," explained Andrew Siegmund, Application Migration Specialist for CAST, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that's no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, explored how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He expla...
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone inn...
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
DevOps promotes continuous improvement through a culture of collaboration. But in real terms, how do you: Integrate activities across diverse teams and services? Make objective decisions with system-wide visibility? Use feedback loops to enable learning and improvement? With technology insights and real-world examples, in his general session at @DevOpsSummit, at 21st Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, explored how leading organizations use data-driven DevOps to clos...
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, discussed how they built...
The dynamic nature of the cloud means that change is a constant when it comes to modern cloud-based infrastructure. Delivering modern applications to end users, therefore, is a constantly shifting challenge. Delivery automation helps IT Ops teams ensure that apps are providing an optimal end user experience over hybrid-cloud and multi-cloud environments, no matter what the current state of the infrastructure is. To employ a delivery automation strategy that reflects your business rules, making r...
The past few years have brought a sea change in the way applications are architected, developed, and consumed—increasing both the complexity of testing and the business impact of software failures. How can software testing professionals keep pace with modern application delivery, given the trends that impact both architectures (cloud, microservices, and APIs) and processes (DevOps, agile, and continuous delivery)? This is where continuous testing comes in. D
Modern software design has fundamentally changed how we manage applications, causing many to turn to containers as the new virtual machine for resource management. As container adoption grows beyond stateless applications to stateful workloads, the need for persistent storage is foundational - something customers routinely cite as a top pain point. In his session at @DevOpsSummit at 21st Cloud Expo, Bill Borsari, Head of Systems Engineering at Datera, explored how organizations can reap the bene...
No hype cycles or predictions of a gazillion things here. IoT is here. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, an Associate Partner of Analytics, IoT & Cybersecurity at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He also discussed the evaluation of communication standards and IoT messaging protocols, data...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
Digital transformation is about embracing digital technologies into a company's culture to better connect with its customers, automate processes, create better tools, enter new markets, etc. Such a transformation requires continuous orchestration across teams and an environment based on open collaboration and daily experiments. In his session at 21st Cloud Expo, Alex Casalboni, Technical (Cloud) Evangelist at Cloud Academy, explored and discussed the most urgent unsolved challenges to achieve f...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...